Joel S Rimes
Overview
Explore the profile of Joel S Rimes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atkin-Smith G, Santavanond J, Light A, Rimes J, Samson A, Er J, et al.
Nat Commun
. 2024 Oct;
15(1):8802.
PMID: 39438460
Endothelial cells are integral components of all vasculature within complex organisms. As they line the blood vessel wall, endothelial cells are constantly exposed to a variety of molecular factors and...
2.
Yip R, Rimes J, Capaldo B, Vaillant F, Mouchemore K, Pal B, et al.
Nat Commun
. 2021 Nov;
12(1):6920.
PMID: 34836954
Bone marrow is a preferred metastatic site for multiple solid tumours and is associated with poor prognosis and significant morbidity. Accumulating evidence indicates that cancer cells colonise specialised niches within...
3.
Samson A, Fitzgibbon C, Patel K, Hildebrand J, Whitehead L, Rimes J, et al.
Cell Death Differ
. 2021 Feb;
28(7):2126-2144.
PMID: 33589776
Necroptosis is a lytic, inflammatory cell death pathway that is dysregulated in many human pathologies. The pathway is executed by a core machinery comprising the RIPK1 and RIPK3 kinases, which...
4.
Kong I, Rimes J, Light A, Todorovski I, Jones S, Morand E, et al.
Cell Rep
. 2020 Oct;
33(3):108290.
PMID: 33086063
JQ1 is a BET-bromodomain inhibitor that has immunomodulatory effects. However, the precise molecular mechanism that JQ1 targets to elicit changes in antibody production is not understood. Our results show that...